TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01954290
Drug: Conivaptan
Normalized name: Conivaptan
DrugBank: Conivaptan (DB00872)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous conivaptan 20 mg infused over 30 minutes as a loading dose, followed by a continuous infusion of 20 mg over 24 hours (0.83 mg/hour) for 2-4 days; may increase to a maximum dose of 40 mg over 24 hours (1.7 mg/hour) if serum sodium is not rising sufficiently; total duration of therapy not to exceed 4 days.
Study: NCT01954290
Drug: Mannitol
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mannitol given at the dose of 0.5 to 1.0 gm/kg IV over 10-20 minutes. Maximum effect is seen in 20 minutes and duration of action is 4 hours. Repeat doses of 0.25 to 0.5 gm/kg Q 4-6 hours are normally frequently used.
Study: NCT02813538
Drug: Indocyanine green clearance
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: To evaluate liver function by injection of indocyanine green by a peripheral vein and measure its clearance
Study: NCT00216008
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00216008
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02477098
Drug: preoperative 0.5% ropivacaine hydrochloride preoperative
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Before surgery (Pre RSB) , a bilateral RSB with ropivacaine hydrochloride will be performed under ultrasound guidance by one anaesthesiologist.At the end of surgery, a bilateral RSB with saline will be performed under ultrasound guidance by one anaesthesiologist.
Study: NCT02477098
Drug: postoperative 0.5% Ropivacaine hydrochloride
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Before surgery, a bilateral RSB with saline will be performed under ultrasound guidance by one anaesthesiologist.At the end of surgery, a bilateral RSB with ropivacaine hydrochloride will be performed under ultrasound guidance by one anaesthesiologist.
Study: NCT00919022
Drug: Cyproterone Acetate (Androcur, BAY94-8367)
Normalized name: cyproterone
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in regular clinical practice receiving Androcur according to local drug information
Study: NCT01186653
Drug: budesonide / formoterol
Normalized name: budesonide / formoterol
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: budesonide / formoterol, 400 micrograms/9 micrograms one IH bd
Study: NCT01186653
Drug: fluticasone/salmeterol
Normalized name: FLUTICASONE/SALMETEROL
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: fluticasone/salmeterol, 250 micrograms/25 micrograms two puffs bd, dose as per NICE guidelines
Study: NCT02819596
Drug: Savolitinib
Normalized name: savolitinib
DrugBank: Savolitinib (DB12048)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02819596
Drug: Tremelimumab
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02333331
Drug: bimagrumab
Normalized name: Bimagrumab
DrugBank: Bimagrumab (DB12584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimagrumab will be administered as an intravenous infusion starting on Day 1 until week 21.
Study: NCT02133937
Drug: gantenerumab
Normalized name: Gantenerumab
DrugBank: Gantenerumab (DB12034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutaneous injection of a high concentration liquid formulation
Study: NCT02133937
Drug: gantenerumab
Normalized name: Gantenerumab
DrugBank: Gantenerumab (DB12034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutaneous injection of a lyophilized formulation
Study: NCT00738738
Drug: PD-0332334
Normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dosage from: 50-100 mg oral capsule Dosage and frequency: 50-350 mg once or twice a day Duration: 6 months
Study: NCT02381158
Drug: Nebulized beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized beclomethasone dipropionate applied for 12 weeks with a dose of 400 µg twice a day (total dose 800 µg)
Study: NCT01655511
Drug: Tafamidis
Normalized name: Tafamidis
DrugBank: Tafamidis (DB11644)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 240 mg, solution, single dose
Study: NCT01655511
Drug: Tafamidis
Normalized name: Tafamidis
DrugBank: Tafamidis (DB11644)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 480 mg, solution, single dose
Study: NCT01655511
Drug: Tafamidis
Normalized name: Tafamidis
DrugBank: Tafamidis (DB11644)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TBD dose will be a single dose if \< 720 mg or a loading dose followed by additional dose if \> 720 mg.
Study: NCT01878565
Drug: GM-CSF control
Normalized name: axatilimab-csfr
DrugBank: Axatilimab (DB16388)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given four times in week 0, 4, 12 and 24. At each time of treatment, the patients will be hospitalized and treated with saline placebo intramuscularly or subcutaneously at day 2, 3, 4, 5, 6.
Study: NCT01521845
Drug: omega 3
Normalized name: omega 3,6
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 gram omega 3 (400mg EPA and 200mg DHA) 12hours before PCI
Study: NCT01451515
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally (PO).
Study: NCT01451515
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given intravenously (IV).
Study: NCT01451515
Drug: Daunorubicin
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV.
Study: NCT01451515
Drug: PEG-asparaginase
Normalized name: Peg-asparaginase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given intramuscularly (IM) or IV.
Study: NCT01451515
Drug: Erwinia asparaginase
Normalized name: Erwinia asparaginase
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IM or IV if allergy occurs with the first or second PEG-asparaginase dose.
Study: NCT01451515
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or IT.
Study: NCT01451515
Drug: Thioguanine
Normalized name: Thioguanine
DrugBank: Tioguanine (DB00352)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO.
Study: NCT01451515
Drug: Clofarabine
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV.
Study: NCT01451515
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO or IV.
Study: NCT01451515
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV.
Study: NCT01563601
Drug: Obatoclax Mesylate, Carboplatine and Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Obatoclax Mesylate:~30 mg fixed dose;administered IV on days 1-3 every 21 days for 6 cycles. Maintenance therapy (optional and only if documented CR or PR) with obatoclax mesylate is administered at the same IV dose on days 1-3 every 21 days until disease progression or death.~Carboplatin:~Dose targeted at AUC of 5; administered IV on Day 1 only every 21 days for 6 cycles~Etoposide:~100mg/m2 administered IV on Days 1-3 every 21days for 6 cycles
Study: NCT01563601
Drug: Carboplatin and Etoposide
Normalized name: Carboplatin
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin:~Dose targeted at AUC of 5 administered IV on Day 1 only every 21 days for 6 cycles.~Etoposide:~100mg/m2 administered IV on Days 1-3 every 21 days for 6 cycles
Study: NCT03623750
Drug: EGFR-TK Inhibitor
Normalized name: Egfr t790m inhibitor pf-06747775
DrugBank: Mavelertinib (DB16228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will commence daily oral therapy with the EGFR TKI afatinib as soon as possible, preferably on the same day as low dose cyclophosphamide. Afatinib will be prescribed according to the Summary of Product Characteristics (SmPC) of the product, and will continue in nominal 21-day cycles for as long as clinically indicated.
Study: NCT03918993
Drug: Tadalafil 5mg tablet
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once-a-day 5 mg dose of tadalafil for 8 weeks
Study: NCT01855555
Drug: sedation with propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: When a patient is admitted to the Pediatric Sedation Center, a presedation assessment is performed by hospitalists. Then Pediatric sedation is performed by protocol in the sedation unit.~Data on demographics, primary illness, ASA, snoring history, URI symptom, medications used, procedure and recovery times, medication doses, outcomes of anesthesia, airway interventions and adverse events will be reported.
Study: NCT03047005
Drug: NB medication (Naltrexone Bupropion combination)
Normalized name: Nb
DrugBank: Niobium (DB13031)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NB medication
Study: NCT02132390
Drug: Goserelin
Normalized name: Goserelin
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02132390
Drug: Toremifene
Normalized name: Toremifene
DrugBank: Toremifene (DB00539)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04819828
Drug: Tamsulosin
Normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tamsulosin (0.4 mg/day) for eight weeks.
Study: NCT03842709
Drug: Pramipexole Oral Tablet
Normalized name: pramipexole Oral Tablet
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initial dosage of 0.125 mg pramipexole daily, potentially titrated upward in 0.125 increments to a maximum of 0.5 mg daily, for 4 weeks.
Study: NCT01023282
Drug: ACR325
Normalized name: ACR325
DrugBank: ACR325 (DB05196)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, dose titration from 25 mg to 75 mg bid or matching placebo. Duration of dosing: 3 weeks
Study: NCT01939379
Drug: Morphine PCA started at the end of surgery, 1 Percocet 1/325mg every 4 hours; may receive a second Percocet if needed.
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01939379
Drug: For the 30ml ropivacaine the intervention would be the subject can request extra pain medication which would be Percocet and/or morphine PCA.
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00644579
Drug: bLAC
Normalized name: BLACK 2
DrugBank: Black olive (DB10547)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bLAC high and low dose and placebo
Study: NCT00704106
Drug: Entecavir
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 or 1 mg dose qd
Study: NCT04560127
Drug: Camrelizumab combination with Apatinib
Normalized name: aminophenazone, combinations with psycholeptics
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib (250mg p.o. q.d.) combined with Camrelizumab (200mg, iv, q2w)
Study: NCT02835729
Drug: Idarubicin
Normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy
Study: NCT02835729
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy
Study: NCT02835729
Drug: Indoximod Freebase
Normalized name: Indoximod
DrugBank: Indoximod (DB12827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDO pathway inhibitor
Study: NCT02835729
Drug: Indoximod HCL F1
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Indoximod (DB12827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDO pathway inhibitor
Study: NCT02835729
Drug: Indoximod HCL F2
Normalized name: Indoximod
DrugBank: Indoximod (DB12827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDO pathway inhibitor
Study: NCT01089855
Drug: Carbamazepine
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00091793
Drug: AMG 162
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/mL denosumab given day 1, month 6, month 12 and month 18
Study: NCT00002516
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002516
Drug: ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002516
Drug: mesna
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002516
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03271489
Drug: Elagolix
Normalized name: ELAGOLIX
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets
Study: NCT00080327
Drug: Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablets, Oral, 2mg, Once daily, 6 weeks.
Study: NCT00080327
Drug: Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablets, Oral, 5mg, Once daily, 6 weeks.
Study: NCT00080327
Drug: Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablets, Oral, 10mg, Once daily, 6 weeks.
Study: NCT00195351
Drug: ceftriaxone sodium + metronidazole
Normalized name: Ceftriaxone Sodium
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftriaxone sodium 2 g once daily intravenously plus metronidazole 1 g to 2 g daily given in divided doses intravenously. Test article should be administered for a minimum of 4 days and up to 14 days at the discretion of the investigator.
Study: NCT02404506
Drug: Eribulin mesilate
Normalized name: Eribulin mesilate
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eribulin mesiylate 1.1mg/m2 d1, 8 every 3 weeks until Progressive disease PD
Study: NCT04255134
Drug: Abatacept Injection
Normalized name: abatacept Injection
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will be randomized to treatment with either abatacept or adalimumab
Study: NCT04255134
Drug: Adalimumab Injection
Normalized name: adalimumab Injection
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will be randomized to treatment with either abatacept or adalimumab
Study: NCT03797443
Drug: nab paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 30 minute IV infusions on days 1 and 8 repeated every 21 days, followed by Cisplatin
Study: NCT03797443
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60minute IV infusion on days 1 and 8 repeated every 21 days followed by Gemcitabine
Study: NCT03797443
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 30 minute IV infusion on days 1 and 8 repeated every 21 days
Study: NCT01813487
Drug: HBsAg vaccine with Entecavir
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00749632
Drug: oxybutynin
Normalized name: Oxybutynin
DrugBank: Oxybutynin (DB01062)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: low dose oxybutynin administered daily
Study: NCT00749632
Drug: oxybutynin
Normalized name: Oxybutynin
DrugBank: Oxybutynin (DB01062)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: middle dose oxybutynin administered daily
Study: NCT00749632
Drug: oxybutynin
Normalized name: Oxybutynin
DrugBank: Oxybutynin (DB01062)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: high dose oxybutynin administered daily
Study: NCT03867253
Drug: ORY-2001 Low dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.6mg ORY-2001 capsule
Study: NCT03867253
Drug: ORY-2001 High dose
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2mg ORY-2001 capsule
Study: NCT05634564
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab 200mg administered intravenously on Days 1 of every 3 weeks.
Study: NCT05634564
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine 1000 mg/m\^2 administered intravenously on Days 1 \& 8 of every 3 weeks.
Study: NCT05634564
Drug: Nab paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Gemcitabine 125 mg/m\^2 administered intravenously on Days 1 \& 8 of every 3 weeks.
Study: NCT00073944
Drug: forodesine hydrochloride
Normalized name: Forodesine hydrochloride
DrugBank: Forodesine (DB06185)
Approvals — FDA: no, EMA: no, PMDA: yes
Study: NCT01480180
Drug: turoctocog alfa pegol
Normalized name: Turoctocog alfa pegol
DrugBank: Turoctocog alfa pegol (DB14738)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Administered i.v.
Study: NCT00004046
Drug: exatecan mesylate
Normalized name: mesylate
DrugBank: Exatecan (DB12185)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04977544
Drug: Sertraline
Normalized name: Sertraline
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline was given as a single drug, with an initial dose of 50 mg/d, and gradually increased to the maximum dose of 200 mg/d after 2 weeks. The treating physician will determine the specific dose adjustment according to the patient's condition.
Study: NCT00761540
Drug: liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide for s.c. injection once daily: dose step 1 (9 subjects)
Study: NCT00761540
Drug: liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide for s.c. injection once daily: dose step 1, followed by dose step 2 (9 subjects)
Study: NCT00761540
Drug: liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide for s.c. injection once daily: dose step 1, followed by dose steps 2 and 3 (9 subjects)
Study: NCT03738956
Drug: Tofacitinib
Normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The study subjects fulfilling the inclusion criteria will receive tofacitinib 5mg BD.~All the patients in the study group will go through disease history, clinical examination and baseline investigations. Baseline charachteristics and variables will be recorded at initiation of therapy, 4th, 12th and 24th week. Primary endpoint of efficacy will be assessed using ASAS 20 response at the end of 12 th wk. At the end of 12 th week, those patients will achieve primary endpoint will continue with the same dose and those patients who will not achieve primary endpoint will be put on tofacitinib10 mg BD. Those patients who will not respond to treatment at the end of 24 th wk will discontinue the therapy and put on alternative treatment.
Study: NCT00729430
Drug: Omega-3 Fatty Acids (Fish Oil Supplements)
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 grams of omega-3 fatty acids taken orally once per day for 6 months
Study: NCT03444025
Drug: Goserelin
Normalized name: Goserelin
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Goserelin is Luteinizing hormone releasing hormone (LHRH) analogue.
Study: NCT00553787
Drug: VI-0521
Normalized name: VIS-410
DrugBank: VIS-410 (DB19067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: phentermine 15 mg and topiramate 92 mg, po once daily
Study: NCT00553787
Drug: VI-0521
Normalized name: VIS-410
DrugBank: VIS-410 (DB19067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: phentermine 7.5 mg and topiramate 46 mg, po once daily
Study: NCT00553787
Drug: VI-0521
Normalized name: VIS-410
DrugBank: VIS-410 (DB19067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01088412
Drug: Somatropin (recombinant deoxyribonucleic acid [rDNA] origin)
Normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose, frequency and duration at discretion of attending physician.
Study: NCT02285010
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin (150 mg) one capsule is prescribed to the patient 60 min prior to the surgery.~Ringer Lactate Solution preload 15 mL/kg prior to surgery. Spinal anesthesia is done with 0.5% Heavy bupivacaine + morphine 0.2 mg total volume 3.0 - 3.6 mL. IV PCA Morphine is applied at PACU (bolus dose only 1 mg, lockout interval 5 min, 4 hr limit 35 mg). As soon as the patient is allowed to sip, paracetamol (500 mg) 1 tab PO every 6 hours is prescribed.
Study: NCT00001542
Drug: fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00152256
Drug: Asoprisnil
Normalized name: Asoprisnil
DrugBank: Asoprisnil (DB06680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asoprisnil 10 mg Tablet, oral Daily for 6 months
Study: NCT00152256
Drug: Asoprisnil
Normalized name: Asoprisnil
DrugBank: Asoprisnil (DB06680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asoprisnil 25mg Tablet, oral Daily for 6 months
Study: NCT01870466
Drug: Cilostazol
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cilostazol bid for 7 days
Study: NCT01591330
Drug: LY2140023 Reference form
Normalized name: LY2140023
DrugBank: LY2140023 (DB05096)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80-mg tablet administered orally
Study: NCT01591330
Drug: LY2140023 Test-Low
Normalized name: ethinyl estradiol
DrugBank: LY2140023 (DB05096)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80-mg tablet administered orally
Study: NCT01591330
Drug: LY2140023 Test-Medium
Normalized name: Medium-Chain Triglycerides
DrugBank: LY2140023 (DB05096)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80-mg tablet administered orally
Study: NCT01591330
Drug: LY2140023 Test-High
Normalized name: high-density polyethylene
DrugBank: LY2140023 (DB05096)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80-mg tablet administered orally
Study: NCT01814423
Drug: Chloroquine-base 50 mg
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01814423
Drug: Chloroquine-base 70 mg
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no